Coffee and Cardiovascular Health: Is There a Benefit?

First Rivaroxaban Generics (2.5 mg) Get FDA Approval

News

Slideshow

ACC 2022

Consuming caffeine has been thought to induce cardiac dysrhythmias, leaving patients and physicians to worry that drinking coffee can worsen or trigger certain cardiovascular issues. However, findings from 3 new studies suggest consuming coffee on a daily basis can benefit persons with and without cardiovascular disease. The studies will be presented at the American College of Cardiology’s 71st Scientific Sessions, held April 2-4, 2022. In the slides below, find a brief preview of topline results that may inform clinical practice.

Related Content

March 5th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.

August 30th 2023

Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Dupilumab Cardiometabolic Safety in Real-World Study Supports Clinical Trial Evidence / image credit University of Lubeck, Germany

February 21st 2025

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

October 29th 2020

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

February 10th 2025

Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

February 5th 2025

First Rivaroxaban Generics (2.5 mg) Get FDA Approval

Elevated HbA1c/HDL-C ratios significantly increased stroke risk, even after adjusting for confounding factors, reported authors of a recent study.

Related Content

Cardiology

Conference

ACC

March 5th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.

August 30th 2023

Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

February 21st 2025

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

October 29th 2020

FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

February 10th 2025

Investigators Identify Hemoglobin A1c/HDL-C as a Predictor of Stroke Risk in Older Adults

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

February 5th 2025